瘤学随机对照试验的同行评审报告可能是短暂和肤浅的
Patricia Logullo1, Angela MacCarthy1, Shona Kirtley1
1Centre for Statistics in Medicine, UK EQUATOR Centre, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford UK.
Journal of clinical epidemiology
|July 2, 2025
概括
瘤学随机对照试验 (RCT) 的公开同行评审报告通常是简短的,缺乏建设性. 审查人员很少评估关键方面,如数据可用性或协议遵守,限制他们的价值.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 科学出版 科研出版
背景情况:
- 开放的同行评审 (OPR) 旨在提高科学出版的透明度和质量.
- 随机对照试验 (RCT) 对于推进癌症治疗和患者护理至关重要.
- 同行评审报告的质量直接影响发表的研究的可靠性和有用性.
研究的目的:
- 批判性地评估伴随瘤学RCT的公开同行评审报告的质量.
- 评估这些OPR报告的内容,清晰度和完整性.
- 确定审查者是否充分解决RCT方法论,报告和影响的关键方面.
主要方法:
- 一个系统的搜索和采样2021年在62个生物医学中央期刊中发表的瘤学RCT的OPR报告.
- 两个调查人员对59份第一轮同行评审报告进行了独立评估,第三位作者负责解决冲突.
- 评价审查员对手稿重要性,方法稳定性,结果解释,讨论和RCT报告标准的评论.
主要成果:
- 同行评审报告的中位数为276个字,只有19%是建设性的.
- 虽然78%的审稿人评论了方法,但只有25%的审稿人讨论了结论的充分性,9%的审稿人讨论了结果的适用性.
- 仅有7%的报告讨论了开放式研究实践,包括协议偏差,报告完整性和数据共享.
结论:
- 瘤学RCT的同行评审报告往往是肤浅的,缺乏建设性的反.
- 对研究结论,协议遵守和数据透明度等关键要素的关注不足.
- 目前OPR报告的质量对于寻求改进手稿的作者或做出出版决策的编辑来说具有有限的价值.
相关概念视频
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
182
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
182
01:21Cancer Survival Analysis
458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
01:12Hazard Ratio
259
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
259
01:20Comparing the Survival Analysis of Two or More Groups
299
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
299
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K